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Abstract
Introduction Cardiovascular surgery with cardiopulmonary
bypass (CPB) has improved in past decades, but inflammatory
activation in this setting is still unpredictable and is associated
with several postoperative complications. Perioperative levels of
macrophage migration inhibitory factor (MIF) and other
inflammatory mediators could be implicated in adverse
outcomes in cardiac surgery.
Methods Serum levels of MIF, monocyte chemoattractant
protein (MCP)-1, soluble CD40 ligand, IL-6 and IL-10 from 93
patients subjected to CPB were measured by enzyme-linked
immunosorbent assay and compared with specific and global
postoperative organ dysfunctions through multiple organ
dysfunction score (MODS) and sequential organ failure
assessment (SOFA).
Results Most of the cytokines measured had a peak of
production between 3 and 6 hours after CPB, but maximum
levels of MIF occurred earlier, at the cessation of CPB. Among
specific organ dysfunctions, the most frequent was
hematological, occurring in 82% of the patients. Circulatory
impairment was observed in 73.1% of the patients, and 51% of
these needed inotropics or vasopressors within the first 24
hours after surgery. The third most frequent dysfunction was
pulmonary, occurring in 48.4% of the patients. Preoperative
levels of MIF showed a relevant direct correlation with the
intensity of global organ dysfunction measured by SOFA (ρ =
0.46, p < 0.001) and MODS (ρ = 0.50, p < 0.001) on the third
day after surgery. MCP-1 production was associated with
postoperative thrombocytopenia, and MIF was related to the use
of a high dose of vasopressors in patients with cardiovascular
impairment and also to lower values of the ratio of partial arterial
oxygen tension (PaO2) to fraction of inspired oxygen (FiO2)
registered in the first 24 hours after CPB.
Conclusion Despite the multifactorial nature of specific or
multiple organ dysfunctions, MIF should be explored as a
predicting factor of organ dysfunction, or even as a potential
therapeutic target in decreasing postoperative complications.
Introduction
Cardiovascular surgery with cardiopulmonary bypass (CPB) is
known to be associated with many aggressive factors, includ-
ing operative trauma, cardioplegia, ischemia-reperfusion injury
and the contact of blood with bioactive surfaces, potentially
related to platelet activation and inflammation [1]. Lipopoly-
saccharide (LPS) has been proved to circulate after cardiac
surgery with CPB [2] and, despite substantial technological
improvements in past decades, an acute transcriptional
response of genes involved in the innate immune response
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occurs, which can lead to systemic inflammation and postop-
erative organ dysfunction [3].
Several circulating inflammatory mediators, including pro-
inflammatory and anti-inflammatory cytokines [4] and chemok-
ines [5], could be associated with postoperative outcomes.
Macrophage migration inhibitory factor (MIF) has been consid-
ered a central mediator of the innate immune response as a
natural ligand of CD74 and has been implicated in cellular sig-
naling and activation [6]. Moreover, MIF is known to regulate
p53-induced apoptosis, which is one of the main mechanisms
of immune activation control [7]. Constitutively expressed, MIF
is stored in intracellular granules and is rapidly secreted under
inflammatory stimuli, exerting powerful pro-inflammatory
actions (reviewed in [8]). Previous studies have demonstrated
that high MIF levels might have implications for pathological
disorders in patients with systemic inflammatory response syn-
drome, severe sepsis, and acute respiratory distress syn-
drome [9-12].
The correlation of poor outcomes and high levels of MIF, par-
ticularly in patients in an injury setting, could be explained both
by the pro-inflammatory and immunoregulatory properties of
this cytokine, especially by modulating the expression of Toll-
like receptor-4, a signal-transducing molecule of the LPS
receptor complex, and the signal transduction cascade inher-
ent in its activation [13]. In cardiac surgery, MIF levels six hours
after CPB were associated with a poorer postoperative pulmo-
nary short-course outcome [14].
Chemotactic proteins have an important role in evoking inflam-
matory responses. Monocyte chemoattractant protein (MCP)-
1 has the property of chemoattracting mononuclear phago-
cytes, natural killer cells, T cells, mast cells, and basophils. Del-
eterious sequelae have been attributed to its expression. It has
been implicated in transendothelial monocyte recruitment to
sites of inflammation. Moreover, MCP-1 can induce respiratory
burst activity and stimulate lysosomal enzyme release from
monocytes and also contributes to tissue damage [15].
Soluble CD40 ligand (sCD40L), a member of the TNF family
produced by activated platelets, upregulates the expression of
inflammatory adhesion receptors and cellular activators, and
circulates in response to cardiac surgery with CPB [16].
IL-6 is a cytokine with recognized pro-inflammatory and anti-
inflammatory properties that acts as an indicator of intensity of
inflammatory response [17]. IL-10 decreases the LPS-induced
production of pro-inflammatory cytokines by macrophages as
an attempt to modulate host response to injury [18], which is
essential in re-establishing homeostasis after trauma.
The present study attempts to evaluate preoperative, perioper-
ative and postoperative circulating levels of MIF and other
inflammatory markers, to explore eventual associations
between them and postoperative organ dysfunctions.
Materials and methods
This prospective study was approved by the institutional
review board and ethical committee for research of the Pro
Cardiaco Hospital, Rio de Janeiro, Brazil, and was performed
in a research laboratory associated with the surgical intensive
care unit in a tertiary care cardiology hospital. Under informed
consent, patients who underwent major cardiovascular tho-
racic operations from August 2004 to August 2005, in both
elective and non-elective settings, were enrolled consecu-
tively. We excluded patients with neoplastic or chronic inflam-
matory diseases, and those under immunomodulatory
treatment or drugs, including steroids, aprotinin, coagulation
factors, and non-steroid anti-inflammatory agents.
Anesthesia was performed in accordance with institutional
standards [14]. After anticoagulation with sodium heparin,
normothermic (34 to 37°C) CPB was performed with a contin-
uous-flow membrane oxygenator (DMG-Shunt; DMG Equipa-
mentos Médicos, Duque de Caxias, Brazil). The CPB priming
solution consisted of mannitol and Ringer's solution, in a final
volume of 2,000 ml. Cardioplegia was induced and maintained
by way of St Thomas solutions.
Table 1
Demographics and perioperative characteristics of the 
population under study
Characteristic Value
Demographic
Male sex 60 (64.5%)
Age, years 66.2 ± 11.6
Body mass index 25.9 ± 6.5
EuroSCORE 4.58 (2–7)
NYHA I and II, n 36 (38.8%)
NYHA III and IV, n 57 (61.2%)
Perioperative characteristics (n = 93)
Duration of CPB, minutes) 100 (80–130)
Intraoperative fluid balance, 
ml/kg per hour
9.09 (6.31–11.36)
Blood transfusion, n 45 (48.4%)
CABS, n 60 (64.5%)
CABS + open-heart surgery, 
n
14 (15.1%)
Valve replacement/repair, n 16 (17.2%)
Aortic surgery, n 3 (3.2%)
Errors are SEM; ranges are from first to third quartile. CABS, 
coronary artery bypass surgery; CPB, cardiopulmonary bypass; 
EuroSCORE, European System for Cardiac Operative Risk 
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Peripheral blood was harvested immediately before anesthe-
sia induction, at the cessation of CPB, and 3, 6, 10, and 24
hours after the end of CPB. Serum and plasma were sepa-
rated by centrifugation at 800 g for 15 minutes at 4°C and
were kept frozen at -70°C until assayed. Serum levels of MIF,
MCP-1, IL-6, IL-10, and sCD40L were assayed by an enzyme-
linked immunosorbent assay sandwich technique (R & D Sys-
tems, Minneapolis, MN, USA) in accordance with the manu-
facturer's recommendations.
Clinical characteristics including demographics, past medical
history, present surgical intervention, and subsequent hospital
course were recorded. The preoperative risk profile of all
patients was assessed with the European System for Cardiac
Operative Risk Evaluation (EuroSCORE) [19].
Global and specific organ dysfunctions were assessed with
the multiple organ dysfunction score (MODS) [20] and
Sequential Organ Failure Assessment (SOFA) [21] scales,
registered during the first 72 hours after surgery.
Statistical analysis
For the assessment of sequential variations in circulating lev-
els of the markers studied we used an analysis of variance for
repeated measures with the Bonferroni test. Data are shown
as means ± SEM when they had a normal distribution, or as
median (range from first to third quartile) if the distribution was
not normal. Differences between groups were analyzed with
the Mann–Whitney U test. Correlations were assessed with
the Spearman test. Values of p < 0.05 were considered statis-
tically significant. Receiver operating characteristic curves
were constructed to evaluate the diagnostic potential by
means of the area under the curve and the diagnostic accu-
racy of the markers at various cutoff points. The optimal cutoff
value was obtained by calculating the maximum value for the
product of sensitivity and specificity.
Results
The 93 patients included in the study were 66.2 ± 11.6 years
old; 60 (64.5%) were male, and the body mass index was 25.9
± 6.5. The median (range from first to third quartile) Euro-
SCORE was 4.58 (2 to 7). Twenty-nine patients (31%) were
operated on under non-elective conditions, and did not differ
from electively operated patients in age, duration of CPB, or
perioperative blood and fluid balance. Patients who were sub-
jected to cardiac surgery in urgent or emergency settings had
a higher EuroSCORE (6.23 ± 0.75 versus 3.70 ± 0.35; p =
0.001) than electively operated patients. Concerning preoper-
ative cardiopulmonary functional status, patients in New York
Heart Association (NYHA) classes III and IV (n = 57; 61.2%)
Figure 1
Kinetics of inflammatory mediators at anesthesia induction and after cardiopulmonary bypass Kinetics of inflammatory mediators at anesthesia induction and after cardiopulmonary bypass. (a) Macrophage migration inhibitory factor; (b) IL-6, 
(c) monocyte chemoattractant protein-1; (d) soluble CD40 ligand. AI, anesthesia induction; CPB, cardiopulmonary bypass.Critical Care    Vol 10 No 2    de Mendonça-Filho et al.
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predominated over those in NYHA classes I and II (n = 36;
38.8%).
Patients were subjected to coronary artery bypass surgery
(CABS) (n = 60; 64.5%), to CABS associated with intracar-
diac open-heart surgeries (n = 14; 15.1%), to valve replace-
ment and/or repair (n = 16; 17.2%), or to aortic surgery (n =
3; 3.2%). The duration of CPB was 100 (80 to 130) minutes.
Intraoperative fluid balance was 9.09 (6.31 to 11.36) ml/kg
per hour, and 45 patients (48.4%) received perioperative
hemotransfusion. Demographics and preoperative data are
summarized in Table 1.
Postoperative outcomes
The duration of CPB was directly associated with SOFA (p =
0.003, ρ = 0.319) and MODS (p = 0.004, ρ = 0.305) was
measured during the first day after surgery.
For a better understanding of the postoperative outcomes in
the first day, indicators of organ dysfunction were individually
analyzed. According to MODS criteria for specific organ dys-
function, hematological dysfunction occurred in 82% of the
patients. Circulatory impairment occurred in 73.1% of the
studied population, and 51% needed inotropics or vasopres-
sors within the first 24 hours after surgery. The third most fre-
quent organ dysfunction was pulmonary (48.4%), followed by
neurological disturbances (25.8%) and renal impairment
(16%). Postoperative image-documented stroke occurred in
three patients (3.2%). Postoperative levels of bilirubin
remained near the normal range, and did not have a relevant
effect on postoperative global organ dysfunction. The levels of
C-reactive protein (CRP) were 4.9 (2.6 to 7.4) mg/dL on the
first day and 14.7 (10.7 to 21.2) mg/dL on the third day after
surgery.
The overall postoperative mortality in this series was 7.5%
(seven patients), with no significant difference between elec-
tively and non-electively operated patients.
Postoperative kinetic of inflammatory markers
As shown by analysis of variance for repeated measures with
the Bonferroni test (p < 0.05), MIF, MCP-1, and IL-6 exhibit
remarkable changes related to cardiovascular surgery with
CPB. Peak levels of MIF were reached at the end of CPB and
were directly associated with its time course (p = 0.001, ρ =
0.391). Nevertheless, maximum levels of MCP-1 and IL-6 were
only observed three hours after CPB. The levels of sCD40L
did not change significantly until 6 hours after CPB; thereafter
a decline was observed at 10 and 24 hours after CPB (Figure
1). IL-10 was detectable in very few samples and no significant
change was recorded in its circulating level during the studied
period.
No differences were found between inflammatory markers of
elective and non-elective surgical settings, except for higher
postoperative levels of IL-6 (p < 0.05) and for a tendency
toward higher preoperative levels of MIF (p = 0.087) in non-
elective patients.
Preoperative levels of MIF are correlated to multiple 
organ dysfunctions
Preoperative circulating levels of MIF were significantly asso-
ciated with the intensity of organ dysfunction, as measured by
SOFA (p < 0.001, ρ = 0.46) and MODS (p < 0.001, ρ = 0.50),
on the third day after surgery (Figure 2). The upper quartile of
Figure 2
Correlation of preoperative levels of macrophage migration inhibitory  factor (MIF) with postoperative organ failure scores Correlation of preoperative levels of macrophage migration inhibitory 
factor (MIF) with postoperative organ failure scores. (a) Sequential 
Organ Failure Assessment (SOFA) at day 3 after surgery. (b) Multiple 
Organ Dysfunction Score (MODS) at day 3 after surgery. Data are 
shown graphically as a linear regression with 95% confidence intervals.Available online http://ccforum.com/content/10/2/R46
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distribution consisted of patients with SOFA and MODS val-
ues higher than five. It was observed that preoperative levels
of MIF were able to identify these subjects demonstrated by
areas under the receiver operator characteristic curve of
0.767 ± 0.065 for SOFA and 0.794 ± 0.067 for MODS. The
best cutoff value for preoperative MIF was 1,100 pg/ml (four-
fold the value in healthy controls), with sensitivities of 89.5%
and 93.3% and specificities of 64.9% and 66.1% for SOFA
and MODS, respectively. Correspondingly, the retrospective
calculations of power were 85. 3% and 97.1%.
Pressure-adjusted heart rate, the marker of circulatory dys-
function used in MODS, was not associated with circulating
MIF. However, higher levels of MIF 3 hours after CPB and IL-
6 10 hours after CPB were related to the need to use high
doses of vasopressors within the first 24 hours after surgery
(p = 0.017 and p = 0.05, respectively). Notably, levels of MIF
or IL-6 were not significantly different between patients who
needed dobutamine or low doses of vasopressors, and those
who required no catecholamine infusions.
Analysis of the fourth quartile of distribution showed that it was
composed of patients with worse postoperative outcomes.
Patients who presented worse pulmonary performance (ratio
of partial arterial oxygen tension (PaO2) to fraction of inspired
oxygen (FiO2) less than 196) exhibited higher levels of MIF
three hours after CPB (p < 0.001). Moreover, MIF 3 hours
after CPB was inversely associated with PaO2/FiO2 ratio (p <
0.001, ρ = -0.383) and was directly associated with the post-
operative duration of mechanical ventilation (p = 0.011, ρ =
0.265).
With regard to renal function, patients in the fourth quartile
exhibited creatinine levels higher than 1.1 mg/dl in association
with higher levels (p < 0.05) of MIF, MCP-1, and IL-6 within the
first 24 hours after CPB.
MIF, IL-6, and sCD40L levels were not associated with hema-
tological dysfunction. However, patients with a platelet count
lower than 133,000/mm3 exhibited significantly higher levels
of MCP-1 at 3, 6, and 10 hours after CPB (Table 2).
Patients who presented minor postoperative neurological dys-
function, especially manifested as behavioral disturbances,
had higher levels of MIF and MCP-1 production (p < 0.05).
Discussion
This study suggests that higher perioperative levels of MIF and
other inflammatory mediators could be related to specific post-
operative organ dysfunction. Importantly, preoperative MIF
was directly associated with the intensity of global organ dys-
function measured by MODS on the third day after surgery.
Previous studies have associated sustained high levels of
inflammatory markers with poor outcomes in systemic inflam-
matory response syndrome and sepsis [22]. Present data
showed that circulating levels of MIF, IL-6, and MCP-1
increased significantly in response to cardiovascular surgery
Table 2
Correlation of time-related cytokine production with organ dysfunctions measured within 24 hours after surgery
Organ dysfunction Inflammatory markers p
AI After CPB
3 hours 6 hours 10 hours
Circulationa MIF 0.017
IL-10 0.011
IL-6 0.05
Hematologicalb MCP-1 0.014
MCP-1 0.026
MCP-1 0.002
Pulmonaryc MIF 0.041
MIF <0.001
IL-10 0.032
aDefined as noreprinephrine > 1.0 µg/kg per minute; bdefined as platelets < 133,000/mm3; cdefined as a ratio of partial arterial oxygen tension to 
fraction of inspired oxygen of less than 196. AI, anesthesia induction; CPB, cardiopulmonary bypass; MCP, monocyte chemoattractant protein; 
MIF, macrophage migration inhibitory factor.Critical Care    Vol 10 No 2    de Mendonça-Filho et al.
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with CPB, and that maximum levels of MIF occurred before
those of IL-6 and MCP-1. Several specific organ dysfunctions
had correlations with cytokine production in different times.
First, a significant association between postoperative levels of
MIF and pulmonary dysfunction has been reported previously
in a study including patients without previous organ dysfunc-
tion who were subjected to elective coronary artery bypass
surgery [14]. In contrast, the present study also included high-
risk patients subjected to more complex cardiovascular sur-
gery in elective and non-elective settings. In this population,
postoperative levels of MIF – especially between three and six
hours after CPB – were associated not only with pulmonary
dysfunction but also with circulatory dysfunction and MODS at
the third day after surgery. Experimental models confirmed that
MIF is, in fact, implicated in LPS-induced lung injury [22].
Second, postoperative neurological dysfunction was was
slightly and rarely associated with postoperative circulating
levels of MIF. The present study could not reproduce such an
association between cytokine levels and major postoperative
neurological complications, possibly because of the small
population with postoperative stroke presented in this series.
However, minor postoperative neurological complications
were associated with higher postoperative levels of MIF and
MCP-1.
Third, postoperative levels of MIF and IL-6 were higher in
patients presenting postoperative vascular hypo-reactivity,
requiring a high dose of vasopressors. There is experimental
evidence that MIF is involved with the LPS-induced upregula-
tion of inducible nitric oxide synthase, with its consequent pro-
duction of nitric oxide and vasodilation [23].
Fourth, MIF can also be involved with LPS-induced myocardial
dysfunction, through gene transcription of IL-6 and TNF-α
[24]. This study was able to demonstrate an association
between higher postoperative levels of MIF and echocardio-
graphically documented ventricular dysfunction (data not
shown), but failed to correlate MIF levels with clinical out-
comes such as pressure-adjusted heart rate and the need for
inotropic agents.
Fifth, as regards postoperative hematological dysfunction,
MCP-1 was the only marker to exhibit a consistent relation to
postoperative low platelet counts in this study. Previous data
indicated that contact with platelets or mesangial cells stimu-
lates the production of MCP-1 through the CD40/CD40L
pathway and may contribute to the inflammatory response
[25]. In the present study, levels of sCD40L were not directly
associated with platelet count but were negatively associated
with MCP-1, which could reflect a higher conservation of
CD40L on the membrane surface, and therefore would be
more liable to intercellular stimulation.
Some questions pertinent to this work could limit its interpre-
tation. The volume of priming solution can be seen as a limita-
tion because of its hemodiluting effect. This procedure could
underestimate the early postoperative values of circulating lev-
els of cytokines. Moreover, the lack of determination of the
specific sources of cytokines could also interfere with its kinet-
ics, especially considering the cardiopulmonary wash-out at
the end of CPB. In spite of these limitations, the main objec-
tives were achieved. Another limitation was the high variability
of preoperative levels of sCD40L, which could be attributed to
in vitro activation of platelets in a population with high-grade
atherosclerotic disease; this variation possibly jeopardized the
reliable evaluation of perioperative kinetics of this marker and
eventual associations between the circulating levels of this
substance and postoperative outcomes. Last, the lack of a
quantitative analysis of CD40L in cell surfaces would be a bet-
ter way of clarifying sCD40L kinetics.
It has recently been stated that the pattern of cellular reactivity
might be implicated in postoperative organ dysfunction after
cardiac surgery in newborns [26]. In addition, the development
of postoperative organ edema – and presumably dysfunction
– after CBP surgery could be predicted preoperatively, sug-
gesting that it develops in the background of a pre-existing
immune activation [27]. One might therefore speculate that
the inflammatory milieu, especially reflected by circulating lev-
els of MIF, could render patients susceptibility to an increased
inflammatory response [28]. Our results support these find-
ings, suggesting that preoperative immune assessment,
focusing especially on circulating levels of MIF, might be asso-
ciated with postoperative outcome. Despite of the multifacto-
rial nature of specific or multiple organ dysfunctions, MIF shall
be explored as a potential therapeutic target in decreasing
postoperative complications.
Conclusion
This study demonstrates that preoperative MIF is consistently
associated with multiple organ dysfunction after cardiovascu-
lar surgery with CPB. The reproduction of these results in
larger and different populations can contribute to the confirma-
tion of its value as a preoperative risk stratification tool.
Key messages
•  Cardiopulmonary bypass provokes a systemic spread of 
inflammatory mediators, which may be related to post-
operative organ dysfunction.
•  Preoperative circulating levels of macrophage migration 
inhibitory factor (MIF), which is potentially involved in a 
sustained inflammatory response, may be associated 
with postoperative organ dysfunction.
•  The reproduction of these results in a larger population 
might ratify that MIF is a valuable tool in the prediction 
of postoperative outcome.Available online http://ccforum.com/content/10/2/R46
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